Rheumatic complaints in women taking aromatase inhibitors for treatment of hormone-dependent breast cancer

Raffaele Scarpa, Mariangela Atteno, Rosario Peluso, Luisa Costa, Stefania Padula, Dario Di Minno, Francesco Caso, Salvatore Iervolino, Maria Vitiello, Antonio Del Puente

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: The rheumatic adverse effects accompanying treatment with aromatase inhibitors (AIs) in hormone-dependent breast cancer represent an area of clinical relevance and emerging concern. This report describes these rheumatic complaints detailing their clinical pattern. Methods: During 1-year period, 18 consecutive postmenopausal women (mean age, 58.33 years; range, 52Y66 years) in treatment with AIs for hormone-dependent breast cancer (mean duration of therapy, 12.0 months; range, 9.1Y17.7 months) were referred for evaluation in the outpatient clinic of the rheumatology unit in relation to rheumatic complaints. According to a routine protocol planned with oncologists, patient evaluations consisted of a complete clinical examination with careful assessment of rheumatic complaints and related physical symptoms, followed by laboratory testing and a bone scintiscan. In no cases were rheumatic complaints present before AI therapy. Results: On the basis of clinical data and investigations and by applying accepted diagnostic criteria, a diagnosis of an undifferentiated spondyloarthropathy was reached in 10 (55.5%) of the 18 patients studied, and an oligoarthritis was shown in 2 more patients (11.1%), whereas a simple arthralgia was found in the remaining 6 patients (33.3%). In the patients meeting criteria as belonging to a spondyloarthritic subset, a family history positive for psoriasis and celiac disease was shown in 2 and 1 instance, respectively, whereas HLA-CW6 and HLA-B27 were detected in 3 and 1 case. A high serum level of anticyclic citrullinated peptide antibodies was shown in 1 patient with oligoarthritis. Most of the patients (16/18) were treated with nonsteroidal anti-inflammatory drugs or with corticosteroids. Methotrexate (10 mg weekly) was added in 3 of these patients, nonresponders. Aromatase inhibitor discontinuation was needed in the remaining 2 cases with spontaneous resolution of symptoms over time. Conclusions: Data from the present study emphasize a previously unsuspected high prevalence of defined arthritides underlying these rheumatic complaints. Therefore, investigative efforts should be addressed to better clarify the clinical and pathogenetic significance of these important consequences of AI therapy. An accurate monitoring of rheumatic complaints has to be suggested to patients taking AI therapy, with a rapid referral to a rheumatologist in the case of consistent suspicion of an inflammatory arthritis.

Original languageEnglish
Pages (from-to)169-172
Number of pages4
JournalJournal of Clinical Rheumatology
Volume17
Issue number4
DOIs
Publication statusPublished - Jun 2011

Fingerprint

Aromatase Inhibitors
Hormones
Breast Neoplasms
Therapeutics
Spondylarthropathies
HLA-B27 Antigen
Rheumatic Fever
Arthralgia
Rheumatology
Celiac Disease
Ambulatory Care Facilities
Psoriasis
Methotrexate
Arthritis
Adrenal Cortex Hormones
Anti-Inflammatory Agents
Referral and Consultation
Bone and Bones
Peptides
Antibodies

Keywords

  • Aromatase inhibitors
  • Hormone-dependent breast cancer
  • Spondyloarthropathy

ASJC Scopus subject areas

  • Rheumatology

Cite this

Rheumatic complaints in women taking aromatase inhibitors for treatment of hormone-dependent breast cancer. / Scarpa, Raffaele; Atteno, Mariangela; Peluso, Rosario; Costa, Luisa; Padula, Stefania; Minno, Dario Di; Caso, Francesco; Iervolino, Salvatore; Vitiello, Maria; Puente, Antonio Del.

In: Journal of Clinical Rheumatology, Vol. 17, No. 4, 06.2011, p. 169-172.

Research output: Contribution to journalArticle

Scarpa, R, Atteno, M, Peluso, R, Costa, L, Padula, S, Minno, DD, Caso, F, Iervolino, S, Vitiello, M & Puente, AD 2011, 'Rheumatic complaints in women taking aromatase inhibitors for treatment of hormone-dependent breast cancer', Journal of Clinical Rheumatology, vol. 17, no. 4, pp. 169-172. https://doi.org/10.1097/RHU.0b013e31821bfc48
Scarpa, Raffaele ; Atteno, Mariangela ; Peluso, Rosario ; Costa, Luisa ; Padula, Stefania ; Minno, Dario Di ; Caso, Francesco ; Iervolino, Salvatore ; Vitiello, Maria ; Puente, Antonio Del. / Rheumatic complaints in women taking aromatase inhibitors for treatment of hormone-dependent breast cancer. In: Journal of Clinical Rheumatology. 2011 ; Vol. 17, No. 4. pp. 169-172.
@article{8f64513e47ee4e139317e905d24ba777,
title = "Rheumatic complaints in women taking aromatase inhibitors for treatment of hormone-dependent breast cancer",
abstract = "Background: The rheumatic adverse effects accompanying treatment with aromatase inhibitors (AIs) in hormone-dependent breast cancer represent an area of clinical relevance and emerging concern. This report describes these rheumatic complaints detailing their clinical pattern. Methods: During 1-year period, 18 consecutive postmenopausal women (mean age, 58.33 years; range, 52Y66 years) in treatment with AIs for hormone-dependent breast cancer (mean duration of therapy, 12.0 months; range, 9.1Y17.7 months) were referred for evaluation in the outpatient clinic of the rheumatology unit in relation to rheumatic complaints. According to a routine protocol planned with oncologists, patient evaluations consisted of a complete clinical examination with careful assessment of rheumatic complaints and related physical symptoms, followed by laboratory testing and a bone scintiscan. In no cases were rheumatic complaints present before AI therapy. Results: On the basis of clinical data and investigations and by applying accepted diagnostic criteria, a diagnosis of an undifferentiated spondyloarthropathy was reached in 10 (55.5{\%}) of the 18 patients studied, and an oligoarthritis was shown in 2 more patients (11.1{\%}), whereas a simple arthralgia was found in the remaining 6 patients (33.3{\%}). In the patients meeting criteria as belonging to a spondyloarthritic subset, a family history positive for psoriasis and celiac disease was shown in 2 and 1 instance, respectively, whereas HLA-CW6 and HLA-B27 were detected in 3 and 1 case. A high serum level of anticyclic citrullinated peptide antibodies was shown in 1 patient with oligoarthritis. Most of the patients (16/18) were treated with nonsteroidal anti-inflammatory drugs or with corticosteroids. Methotrexate (10 mg weekly) was added in 3 of these patients, nonresponders. Aromatase inhibitor discontinuation was needed in the remaining 2 cases with spontaneous resolution of symptoms over time. Conclusions: Data from the present study emphasize a previously unsuspected high prevalence of defined arthritides underlying these rheumatic complaints. Therefore, investigative efforts should be addressed to better clarify the clinical and pathogenetic significance of these important consequences of AI therapy. An accurate monitoring of rheumatic complaints has to be suggested to patients taking AI therapy, with a rapid referral to a rheumatologist in the case of consistent suspicion of an inflammatory arthritis.",
keywords = "Aromatase inhibitors, Hormone-dependent breast cancer, Spondyloarthropathy",
author = "Raffaele Scarpa and Mariangela Atteno and Rosario Peluso and Luisa Costa and Stefania Padula and Minno, {Dario Di} and Francesco Caso and Salvatore Iervolino and Maria Vitiello and Puente, {Antonio Del}",
year = "2011",
month = "6",
doi = "10.1097/RHU.0b013e31821bfc48",
language = "English",
volume = "17",
pages = "169--172",
journal = "Journal of Clinical Rheumatology",
issn = "1076-1608",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Rheumatic complaints in women taking aromatase inhibitors for treatment of hormone-dependent breast cancer

AU - Scarpa, Raffaele

AU - Atteno, Mariangela

AU - Peluso, Rosario

AU - Costa, Luisa

AU - Padula, Stefania

AU - Minno, Dario Di

AU - Caso, Francesco

AU - Iervolino, Salvatore

AU - Vitiello, Maria

AU - Puente, Antonio Del

PY - 2011/6

Y1 - 2011/6

N2 - Background: The rheumatic adverse effects accompanying treatment with aromatase inhibitors (AIs) in hormone-dependent breast cancer represent an area of clinical relevance and emerging concern. This report describes these rheumatic complaints detailing their clinical pattern. Methods: During 1-year period, 18 consecutive postmenopausal women (mean age, 58.33 years; range, 52Y66 years) in treatment with AIs for hormone-dependent breast cancer (mean duration of therapy, 12.0 months; range, 9.1Y17.7 months) were referred for evaluation in the outpatient clinic of the rheumatology unit in relation to rheumatic complaints. According to a routine protocol planned with oncologists, patient evaluations consisted of a complete clinical examination with careful assessment of rheumatic complaints and related physical symptoms, followed by laboratory testing and a bone scintiscan. In no cases were rheumatic complaints present before AI therapy. Results: On the basis of clinical data and investigations and by applying accepted diagnostic criteria, a diagnosis of an undifferentiated spondyloarthropathy was reached in 10 (55.5%) of the 18 patients studied, and an oligoarthritis was shown in 2 more patients (11.1%), whereas a simple arthralgia was found in the remaining 6 patients (33.3%). In the patients meeting criteria as belonging to a spondyloarthritic subset, a family history positive for psoriasis and celiac disease was shown in 2 and 1 instance, respectively, whereas HLA-CW6 and HLA-B27 were detected in 3 and 1 case. A high serum level of anticyclic citrullinated peptide antibodies was shown in 1 patient with oligoarthritis. Most of the patients (16/18) were treated with nonsteroidal anti-inflammatory drugs or with corticosteroids. Methotrexate (10 mg weekly) was added in 3 of these patients, nonresponders. Aromatase inhibitor discontinuation was needed in the remaining 2 cases with spontaneous resolution of symptoms over time. Conclusions: Data from the present study emphasize a previously unsuspected high prevalence of defined arthritides underlying these rheumatic complaints. Therefore, investigative efforts should be addressed to better clarify the clinical and pathogenetic significance of these important consequences of AI therapy. An accurate monitoring of rheumatic complaints has to be suggested to patients taking AI therapy, with a rapid referral to a rheumatologist in the case of consistent suspicion of an inflammatory arthritis.

AB - Background: The rheumatic adverse effects accompanying treatment with aromatase inhibitors (AIs) in hormone-dependent breast cancer represent an area of clinical relevance and emerging concern. This report describes these rheumatic complaints detailing their clinical pattern. Methods: During 1-year period, 18 consecutive postmenopausal women (mean age, 58.33 years; range, 52Y66 years) in treatment with AIs for hormone-dependent breast cancer (mean duration of therapy, 12.0 months; range, 9.1Y17.7 months) were referred for evaluation in the outpatient clinic of the rheumatology unit in relation to rheumatic complaints. According to a routine protocol planned with oncologists, patient evaluations consisted of a complete clinical examination with careful assessment of rheumatic complaints and related physical symptoms, followed by laboratory testing and a bone scintiscan. In no cases were rheumatic complaints present before AI therapy. Results: On the basis of clinical data and investigations and by applying accepted diagnostic criteria, a diagnosis of an undifferentiated spondyloarthropathy was reached in 10 (55.5%) of the 18 patients studied, and an oligoarthritis was shown in 2 more patients (11.1%), whereas a simple arthralgia was found in the remaining 6 patients (33.3%). In the patients meeting criteria as belonging to a spondyloarthritic subset, a family history positive for psoriasis and celiac disease was shown in 2 and 1 instance, respectively, whereas HLA-CW6 and HLA-B27 were detected in 3 and 1 case. A high serum level of anticyclic citrullinated peptide antibodies was shown in 1 patient with oligoarthritis. Most of the patients (16/18) were treated with nonsteroidal anti-inflammatory drugs or with corticosteroids. Methotrexate (10 mg weekly) was added in 3 of these patients, nonresponders. Aromatase inhibitor discontinuation was needed in the remaining 2 cases with spontaneous resolution of symptoms over time. Conclusions: Data from the present study emphasize a previously unsuspected high prevalence of defined arthritides underlying these rheumatic complaints. Therefore, investigative efforts should be addressed to better clarify the clinical and pathogenetic significance of these important consequences of AI therapy. An accurate monitoring of rheumatic complaints has to be suggested to patients taking AI therapy, with a rapid referral to a rheumatologist in the case of consistent suspicion of an inflammatory arthritis.

KW - Aromatase inhibitors

KW - Hormone-dependent breast cancer

KW - Spondyloarthropathy

UR - http://www.scopus.com/inward/record.url?scp=80051782847&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051782847&partnerID=8YFLogxK

U2 - 10.1097/RHU.0b013e31821bfc48

DO - 10.1097/RHU.0b013e31821bfc48

M3 - Article

C2 - 21617557

AN - SCOPUS:80051782847

VL - 17

SP - 169

EP - 172

JO - Journal of Clinical Rheumatology

JF - Journal of Clinical Rheumatology

SN - 1076-1608

IS - 4

ER -